Treeline Biosciences secured a $200 million Series A extension. This funding round brings its total capital raised to $1.1 billion. Investors include ARCH Venture Partners, KKR, and GV.
The Watertown, Massachusetts-based biopharma company also initiated Phase 1 trials for three programs. These include TLN-121, a BCL6 degrader, and TLN-254, an EZH2 inhibitor, both targeting lymphoma. Furthermore, TLN-372, a pan-KRAS inhibitor, entered trials for patients with KRAS-mutated cancers.
Treeline Biosciences focuses on drug discovery for cancer, neurological, and autoimmune diseases. Its pipeline includes small molecules, degraders, and targeted therapy ADCs. The company emphasizes scaled invention and precision medicine in its approach.
Advancing Oncology Pipeline
The company's R&D team utilizes advanced computational tools. This accelerates timelines for new therapies. Treeline Biosciences aims to redefine treatment for serious diseases.
TLN-121 specifically targets BCL6 protein in lymphoma cells. This degrader aims to remove BCL6, avoiding off-target toxicity. Similarly, TLN-372 addresses pan-KRAS mutations, a significant area in cancer research. Existing therapies, like those from Amgen, target specific KRAS variants.
TLN-254, an in-licensed EZH2 inhibitor, previously completed Phase 2 testing. This program targets lymphomas. Companies like Novartis and Genentech also actively develop oncology treatments. Treeline Biosciences continues to build its robust pipeline.
This latest funding supports Treeline Biosciences' ongoing clinical development.
